Diseases requiring laparoscopic total hysterectomy
Conditions
Interventions
Non-opioid anesthesia group:For anesthesia induction, midazolam 0.05 mg/kg, propofol 2 mg/kg, rocuronium 0.6-0.9 mg/kg, etomidate 0.7 mg/kg (administered in two doses, once before intubation and once
Weak-opioid anesthesia group:For anesthesia induction, midazolam 0.05 mg/kg, propofol 2 mg/kg, rocuronium 0.6-0.9 mg/kg, etomidate 0.35 mg/kg (used in two doses, one before intubation and one before s
Sponsors
Huai'an Hospital of Huai'an City
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Female patients scheduled to undergo laparoscopic total hysterectomy; 2. Age between 18 and 65 years; 3. ASA physical status I to III; 4. Body mass index (BMI) 18–30 kg/m^2; 5. Able to listen, speak, read, write, and communicate; 6. Fully informed, voluntarily participating in this study, and have signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Allergy or contraindication to esketamine or other investigational drugs; 2. High risk of significantly increased intracranial pressure, such as intracranial aneurysm, poorly controlled or untreated hypertension (resting systolic blood pressure over 180 mmHg, diastolic over 100 mmHg), untreated or inadequately treated hyperthyroidism, concomitant ischemic heart disease, unstable angina or myocardial infarction within the past 6 months, concomitant congestive heart failure, elevated intraocular pressure (e.g., glaucoma), or penetrating eye injury; 3. Severe liver (Child-Pugh Class C) or kidney dysfunction (creatinine clearance <30 ml/min); 4. Severe cardiovascular or cerebrovascular diseases (myocardial infarction, cardiac arrest, decompensated heart failure, arrhythmias such as second-degree or higher AV block without a pacemaker, congenital heart disease, severe valvular disease, large-area cerebral hemorrhage or infarction, etc.) and respiratory system diseases (history of asthma, acute exacerbation of COPD, history of lung resection, etc.); 5. History of psychiatric disorders; 6. History of long-term use of psychiatric medications/sedatives/analgesics/antidepressants before surgery; 7. Patients who refuse to enroll or other situations deemed unsuitable for participation in this trial by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence and severity of postoperative nausea and vomiting (PONV); | — |
Secondary
| Measure | Time frame |
|---|---|
| General patient condition: age, BMI, ASA classification, operation time, blood loss, urine output, fluid input volume;Perioperative hemodynamic changes: The changes in mean arterial pressure (MAP) and heart rate at each time point, including upon patient's arrival in the operating room (T0), after anesthesia induction (T1), immediately after intubation (T2), before skin incision (T3), 1 minute after skin incision (T4), 30 minutes after the start of surgery (T5), immediately upon entering the post-anesthesia care unit (PACU) (T6), and upon leaving the PACU.;The usage of perioperative vasoactive drugs (drug names, dosages);The time of the first request for pain relief after the surgery and the dosage of the pain medication used;Postoperative NRS pain scores (immediately after extubation, when leaving the PACU, 12 hours after leaving the PACU, 24 hours after leaving the PACU, and 48 hours after leaving the PACU);Awakening time, extubation time, PACU stay time and postoperative hospital stay days;Blood routine test indicators before the operation and on the second day after the operation: white blood cell count, lymphocyte count, neutrophil count, platelet count, hemoglobin level, hematocrit; | — |
Countries
China
Contacts
Public ContactTeng He
Huai'an Hospital of Huai'an City
Outcome results
None listed